The CDK4/6 inhibitor ribociclib (Kisqali) can now be used as first line therapy for pre and peri menopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer after the TGA approved expanded indications for the drug. The new indication covers use of the drug in combination with a luteinizing hormone-releasing hormone (LHRH) agonist and an ...
Ribociclib approved as first line therapy for advanced or metastatic breast cancer
By Sunalie Silva
9 Oct 2019